🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New review of The Current State & Roadmap for AI in Cancer Treatment Decisions in NEJM AI discusses potential of large language models/LLMs in treatment selection. By Olivier Elemento Sean Khozin, MD, MPH Cora Sternberg (subscription $) ai.nejm.org/doi/full/10.10…. NEJM AI EIC is Isaac Kohane

AI Tool Earns U.S. FDA Breakthrough Device Designation PANDA AI scans CTs for lesions with ⚡ 92.9% sensitivity ✅ 99.9% specificity Outperformed radiologists by ⬆️ 34.1% (sensitivity) ⬆️ 6.3% (specificity) targetedonc.com/view/ai-tool-e… via @targetedonc

There’s no Level 1 evidence that our current frequency of post-treatment surveillance imaging & labs reduces the risk of death. (From NEJM piece on pros/cons of routine surveillance protocols, especially relevant in current ctDNA era) – worth a read! nejm.org/doi/full/10.10…

Wow!! 👇🏼👇🏼 Nonoperative Management of Mismatch Repair–Deficient Tumors ⁦NEJM⁩ nejm.org/doi/full/10.10…

A simple move, a big impact: Giving IV magnesium before cisplatin cut kidney injury risk by 20%! Safe. Cheap. Available. JAMA Oncology OncoAlert Oncology Brothers LARVOL jamanetwork.com/journals/jamao…

PEACE V–STORM: Salvage metastasis-directed therapy versus elective nodal radiotherapy☢️for oligorecurrent nodal prostate cancer metastases out on Lancet Oncology thelancet.com/journals/lanon… The PEACE V–STORM trial is a phase 2, randomised study evaluating whether elective nodal

1/5 People living with sickle-cell disease (SCD) face ↑ cancer risk, including #RenalMedullaryCarcinoma. Our latest Immunity study suggests a culprit is the reshaping CD8⁺ T cell chromatin by SCD 👉authors.elsevier.com/sd/article/S10… #MsaouelLab

Artificial Intelligence in the Clinic: Creating Harmony or Just Adding Noise? | American Society of Clinical Oncology Educational Book ascopubs.org/doi/10.1200/ED… #ASCO25

#ASCO2025 🚨 BREAKWATER OS data lands—and it must redefine 1L standard of care in BRAF V600E-mutant mCRC. EC + mFOLFOX6 vs SOC (chemo ± bevacizumab): 📊 PFS: 12.8 vs 7.1 mo (HR 0.53, p < 0.0001) 🧬 OS: 30.3 vs 15.1 mo (HR 0.49, p < 0.0001) ✅ Dual primary endpoints met 🛡️

Pleased to share some first images of Lutetium-177 CA-IX peptide theranostics for metastatic clear cell renal cancer #ASCO25 ASCO. Ga-68 DPI-4452 PET/CT at baseline and on-treatment shown👇 State-of-the-Science: Novel Diagnostics and Therapeutics in Renal Cell Carcinoma

📋Summary of Upper GI oral abstracts #ASCO25 ✅❓CM577: adjuvant nivo after neo-CRT and surgery: DFS benefit sustained, OS numerically high ❌❓LEAP-015: pembro-lenva-ChT vs ChT in 1L of met. GE adenoca: ORR, PFS benefit but no OS benefit ✅Destiny Gastric-04: TDXd vs

Lean body mass–based oxaliplatin dosing reduces peripheral neuropathy in stage III colon cancer without compromising survival! ✅ Lower rates of grade ≥2 oxaliplatin-induced peripheral neuropathy ✅ Better quality of life ✅ No impact on relapse-free survival or overall survival

🚨 New in NEJM : Orforglipron, a once-daily oral GLP‑1, led to ~2% A1c drop & ~16 lb weight loss in T2D (ACHIEVE-1 trial). A non-peptide, no-injection option with classic GLP-1 GI profile. Big step for access & adherence! 🔗nejm.org/doi/full/10.10…

🚨 STELLAR-303 makes history! First-ever Ph3 trial to show OS benefit of IO in MSS CRC 🎯 Years of grit & belief led us here 🥹 Endless thanks to Exelixis⁩ for the trust & Dr. Hecht for leading this global win with me! 🎉 ⁦UPMC Hillman Cancer Center⁩ ir.exelixis.com/news-releases/…

🦠 The gut isn’t just digestion, it’s defense. Microbiome = hidden player in cancer care. ➡️ Shapes immunity, response, toxicity, survival. 🧪 Fiber, FMT, even bacteria-based drugs are in the game now. #Cancer #Immunotherapy #Microbiome #Oncology #GutHealth JAMA

Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy. ja.ma/445u6s6

🏆 "Image of the Year" SNMMI 2025 Can we noninvasively see PD-L1 expression? [¹⁸F]AlF-NOTA-PCP2 PET outperforms FDG in HNSCC. ➕ Tumor-wide PD-L1 mapping ➕ Strong IHC correlation ➕ Immunotherapy guidance 📊 Full breakdown ↓ #ImmunoPET #HNSCC #SNMMI #nucmed #Oncology

Here we propose an algorithmic approach to treatment based on expressed biomarkers and considering magnitude of benefit and anticipated side effects

💊PPI and Immune checkpoint inhibitors Journal of the @NCCN ➡️Retrospective, single center MD Anderson Cancer Center , 1228 patients 🚨More severe upper and lower GI toxicities in PPI users 🚨Worse survival with PPI use 👉jnccn.org/view/journals/… OncoAlert Keith Siau Dr Joseph McCollom DO #cancer

Longer follow up for Enfortumab Vedotin & Pembro in urothelial cancer Annals of Oncology shows mOS at nearly 3 yrs (34 mnths) with 50% of responses (68%) continuing at 2 years! Experience in tox management is important. Duration of therapy uncertain in CR gbr01.safelinks.protection.outlook.com/?url=https%3A%…